Stable Mammalian Cell Line for rAAV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) face challenges such as scalability issues, reliance on wild-type adenovirus helper viruses for replication, and instability due to leaky expression of E1A, which complicates the generation of stable producer cell lines for scalable and safe rAAV production.
Innovation Solution
A mammalian cell line with chromosomally-integrated adenovirus genes E1A, E1B, and a promoter, along with adeno-associated virus genes Rep and Cap, is developed, allowing for the generation of a stable rAAV producer cell line that eliminates the need for live helper viruses and enables efficient, scalable production of high-quality rAAV vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type adenovirus helper virus is used for rAAV production, then virus replication and packaging are enabled, but safety concerns arise due to the need for clearance of helper virus from the final product
Solution Approach 1:
The invention extracts and integrates only the essential adenovirus helper genes (E1A, E1B, E2A, E4, VA RNA) into the producer cell line, separating the helper function from the complete wild-type adenovirus. This allows rAAV production without requiring external helper virus infection, eliminating the need for helper virus clearance while maintaining replication and packaging capabilities
Solution Approach 2:
The invention creates a stable producer cell line that copies the necessary adenovirus helper functions into its genome. Instead of using wild-type adenovirus as a temporary helper, the cell line permanently incorporates and expresses the essential helper genes, making the helper function self-sufficient and eliminating the need for external virus supply
2Productivity
If E1A gene is expressed to drive viral replication, then DNA replication and gene expression are enhanced, but cytostatic and cytotoxic effects occur leading to instability of producer cell lines
Solution Approach 1:
The invention applies local quality by providing regulated expression of E1A only in specific conditions or cell types where high productivity is needed, while maintaining stable producer cell lines for long-term culture. The essential helper genes are integrated into the genome with controlled expression levels that balance replication efficiency with cell stability
Solution Approach 2:
The invention introduces dynamic control of E1A expression through regulatable promoters or inducible systems. This allows the producer cell line to switch between stable maintenance mode and high-productivity mode, expressing E1A only when rAAV production is required, thereby avoiding continuous cytotoxic effects while maintaining production capability
3Productivity
If triple transfection and transient expression in HEK293 is used, then rAAV production is achieved, but scalability is limited
Solution Approach 1:
The invention performs preliminary action by pre-integrating all necessary viral genes (AAV Rep/Cap and adenovirus helper genes) into the producer cell line genome before production. This eliminates the need for transient transfection of multiple plasmids and enables scalable production through stable cell line cultivation and suspension adaptation
Solution Approach 2:
The invention implements self-service by creating autonomous producer cell lines that contain all necessary genetic elements for rAAV production within their own genome. The cells self-sufficiently provide replication functions, packaging functions, and gene expression capabilities without requiring external plasmid supplementation or helper virus infection, enabling scalable manufacturing
4Ease of manufacture
If conventional DNA transduction routes are used for genome modification, then cell line construction is achieved, but unpredictable alterations occur and interchangeability for different virus serotypes is difficult
Solution Approach 1:
The invention applies universality by designing a modular producer cell line system where the essential helper genes and AAV genes are separated into interchangeable modules. This allows the same base producer cell line to be adapted for different AAV serotypes by simply replacing the Cap gene module, providing ease of manufacture while enabling versatility across multiple serotypes
Data Source
AI summary
A mammalian cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operatively linked to the Ad gene, wherein the RTS, the Ad gene, and the promoter are chromosomally-integrated; methods for using the cell for generating a recombinant adeno-associated virus (rAAV) producer host cell; and methods for using the AAV producer host cell to produce, package and purify rAAV.